PANTARHEI BIOSCIENCE B.V.
|PANTARHEI BIOSCIENCE B.V. Patent applications|
|Patent application number||Title||Published|
|20150133413||PHARMACEUTICAL COMPOSITION COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY - The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of:||05-14-2015|
|20150105362||SYNTHESIS OF ESTETROL VIA ESTRONE DERIVED STEROIDS - A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C||04-16-2015|
|20130224233||IMMUNOTHERAPEUTIC METHOD FOR TREATING PROSTATE CANCER - The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8||08-29-2013|
|20120015917||Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy - The present invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen. The progestogen is levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, trimegestone, dienogest, precursors thereof and mixtures thereof. The kit comprises an amount of progestogen equivalent to 30-500 mg of levonorgestrel, 1-40 mg of ethinyl estradiol and 02-100 mg dehydroepiandrosterone.||01-19-2012|
|20110160173||Method Of Treating Human Skin And A Skin Care Composition For Use In Such A Method - One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 μg/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R||06-30-2011|
|20100184736||Treatment of Meconium Aspiration Syndrome with Estrogens - One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that estrogens can be administered using non-invasive modes of administration, e.g. oral or rectal administration. Other aspects of the present invention relate to a suppository for use in newborn infants comprising at least 1 μg of estrogen and to an oral applicator comprising a container holding an aqueous liquid containing micronised estetrol and a metering dispenser for metering the liquid into the oral cavity of a newborn infant.||07-22-2010|
|20100113346||Method of Treating or Preventing Infertility in a Female Mammal and Pharmaceutical Kit for Use in Such Method - The present invention relates to a method of treating infertility in a female mammal that involves controlled ovarian hyperstimulation. The method includes administering to the female a combination of (i) an FSH substance in an amount effective to stimulate follicular development and (ii) a steroid in an effective amount to inhibit or suppress the secretion of luteinising hormone. The steroid can be substances represented by the following formula||05-06-2010|
|20090221540||Method of Treating An Acute Vascular Disorder - The invention relates to a method of treating an acute vascular disorder in a mammal. The method comprises orally administering to the mammal an effective amount of a steroid. The steroid is selected from the group consisting of: substances represented by formula (I), in which R||09-03-2009|
|20090197843||Treatment of Prevention of Unscheduled Bleeding in Women on Progestogen Containing Medication - The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; renin inhibitors and combinations thereof. Other aspects of the invention relate to a pharmaceutical composition containing a RAS suppressor and a progestogen and to a pharmaceutical kit having a plurality of dosage units, wherein at least one dosage unit contains a progestogen; at least one dosage unit contains an estrogen; and at least one dosage unit contains a RAS suppressor.||08-06-2009|
|20080280861||Method of Female Contraception and a Kit For Use Therein - The invention is concerned with a method of contraception in a female mammal of childbearing capability. The method has two alternating phases—a preservation phase and a shedding phase—and has at least two sequences of (a) a preservation phase of 3-12 months involving continuous oral administration to the female of dosage units containing: (i) an estrogen selected from 17β-estradiol, esters of 17β-estradiol and combinations thereof, in an amount equivalent to a daily oral dosage of 2.2-5 mg 17β-estradiol, and (ii) a progestogen in an amount equivalent to a daily oral dosage of 30-750 μg levonorgestrel; and (b) a shedding phase of 4-12 days during which no progestogen is administered. The invention also relates to a contraceptive kit having one or more packaging units that are separately packaged, individually removable oral dosage units for use in the aforementioned contraceptive method.||11-13-2008|
Patent applications by PANTARHEI BIOSCIENCE B.V.